The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Open accessAbstract
OBJECTIVE: To reassess the role of plasmapheresis in the treatment of neurologic disorders. METHODS: We evaluated the available evidence based on a structured literature review for relevant articles from 1995 through September 2009. In addition, due to revision of the definitions of classification of evidence since the publication of the previous American Academy of Neurology assessment in 1996, the evidence cited in that manuscript was reviewed and reclassified. RESULTS AND RECOMMENDATIONS: Plasmapheresis is established as effective and should be offered in severe acute inflammatory demyelinating polyneuropathy (AIDP)/Guillain-Barré syndrome (GBS) and in the short-term management of chronic inflammatory demyelinating polyneuropathy (Class I studies, Level A). Plasmapheresis is established as ineffective and should not be offered for chronic or secondary progressive multiple sclerosis (MS) (Class I studies, Level A). Plasmapheresis is probably effective and should be considered for mild AIDP/GBS, as second-line treatment of steroid-resistant exacerbations in relapsing forms of MS, and for neuropathy associated with immunoglobulin A or immunoglobulin G gammopathy, based on at least one Class I or 2 Class II studies (Level B). Plasmapheresis is probably not effective and should not be considered for neuropathy associated with immunoglobulin M gammopathy, based on one Class I study (Level B). Plasmapheresis is possibly effective and may be considered for acute fulminant demyelinating CNS disease (Level C). There is insufficient evidence to support or refute the use of plasmapheresis for myasthenia gravis, pediatric autoimmune neuropsychiatric disorders associated with streptococcus infection, and Sydenham chorea (Class III evidence, Level U).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Weinshenker, B. G., O'Brien, P. C., Petterson, T. M., Noseworthy, J. H., Lucchinetti, C. F., Dodick, D. W., Pineda, A. A., Stevens, L. N., & Rodriguez, M. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q · Cited by 894
Plasmapheresis and acute Guillain‐Barre syndrome
The Guillain-Barré Syndrome Study Group (1985) · Neurology · doi:10.1212/wnl.35.8.1096 · Cited by 773
Hughes, R., Bensa, S., Willison, H., Van Den Bergh, P., Comi, G., Illa, I., Nobile‐Orazio, E., Van Doorn, P., Dalakas, M., Bojar, M., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1088 · Cited by 628
(1997) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(97)80059-4 · Cited by 610
Perlmutter, S. J., Leitman, S. F., Garvey, M. A., Hamburger, S., Feldman, E., Leonard, H. L., & Swedo, S. E. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12297-3 · Cited by 556
Plasma Exchange in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Dyck, P. J., Daube, J., O'Brien, P., Pineda, A., Low, P. A., Windebank, A. J., & Swanson, C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140801 · Cited by 489
Dyck, P. J., Litchy, W. J., Kratz, K. M., Suarez, G. A., Low, P. A., Pineda, A. A., Windebank, A. J., Karnes, J. L., & O'Brien, P. C. (1994) · Annals of Neurology · doi:10.1002/ana.410360607 · Cited by 471
Hahn, A. F., Bolton, C. F., Pillay, N., Chalk, C., Benstead, T. J., Bril, V., Shumak, K. H., Vandervoort, M. K., & Feasby, T. E. (1996) · Brain · doi:10.1093/brain/119.4.1055 · Cited by 409
Plasma Exchange in Polyneuropathy Associated with Monoclonal Gammopathy of Undetermined Significance
Dyck, P. J., Low, P. A., Windebank, A. J., Jaradeh, S. S., Gosselin, S., Bourque, P., Smith, B. E., Kratz, K. M., Karnes, J. L., Evans, B. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252105 · Cited by 301
Cited by
Chicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Paricio, M., Lorites, J., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12137 · Cited by 143
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Consensus guidelines for the diagnosis and treatment of multiple sclerosis
Yamout, B., Alroughani, R., Al-Jumah, M., Khoury, S., Abouzeid, N., Dahdaleh, M., Alsharoqi, I., Inshasi, J., Hashem, S., Zakaria, M., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.787979 · Cited by 25
Metadata
- Venue
- Neurology
- Published
- 2011-01-18
- Volume
- 76
- Issue
- 3
- Pages
- 294-300
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2143705365
- Cited by
- 369
- References
- 21
- FWCI
- 19.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. https://app.cochat.ai/papers/10.1212/wnl.0b013e318207b1f6
- The paper
- Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (2011). Neurology. https://doi.org/10.1212/wnl.0b013e318207b1f6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
